These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16703976)

  • 1. Treatment challenges and complications with ziconotide monotherapy in established pump patients.
    Thompson JC; Dunbar E; Laye RR
    Pain Physician; 2006 Apr; 9(2):147-52. PubMed ID: 16703976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain.
    Wermeling DP
    Pharmacotherapy; 2005 Aug; 25(8):1084-94. PubMed ID: 16207099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
    Staats PS; Yearwood T; Charapata SG; Presley RW; Wallace MS; Byas-Smith M; Fisher R; Bryce DA; Mangieri EA; Luther RR; Mayo M; McGuire D; Ellis D
    JAMA; 2004 Jan; 291(1):63-70. PubMed ID: 14709577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
    Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
    Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Italian registry on long-term intrathecal ziconotide treatment.
    Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
    Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal ziconotide for refractory chronic pain.
    Lynch SS; Cheng CM; Yee JL
    Ann Pharmacother; 2006; 40(7-8):1293-300. PubMed ID: 16849624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal ziconotide for complex regional pain syndrome: seven case reports.
    Kapural L; Lokey K; Leong MS; Fiekowsky S; Stanton-Hicks M; Sapienza-Crawford AJ; Webster LR
    Pain Pract; 2009; 9(4):296-303. PubMed ID: 19500276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic intrathecal drug administration for the control of intractable pain].
    Taira T
    Brain Nerve; 2008 May; 60(5):509-17. PubMed ID: 18516973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal ziconotide for refractory pain.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jul; 13(7):875-7. PubMed ID: 15212625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A safety review of approved intrathecal analgesics for chronic pain management.
    Chalil A; Staudt MD; Harland TA; Leimer EM; Bhullar R; Argoff CE
    Expert Opin Drug Saf; 2021 Apr; 20(4):439-451. PubMed ID: 33583318
    [No Abstract]   [Full Text] [Related]  

  • 16. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.
    Wallace MS; Rauck R; Fisher R; Charapata SG; Ellis D; Dissanayake S;
    Anesth Analg; 2008 Feb; 106(2):628-37, table of contents. PubMed ID: 18227325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.